Global Atopic Dermatitis Market Size Grows at a CAGR of 9.07%

Introduction

Straits Research released its highly anticipated report, “Global Atopic Dermatitis Market Size & Outlook, 2026-2034”. According to the study, the global market size is valued at USD 19.10 billion in 2025 and is projected to expand to USD 41.57 billion by 2034, registering a compound annual growth rate (CAGR) of 9.07% from 2026-2034.

Market Dynamics

The growth of the global atopic dermatitis market is primarily driven by the increasing adoption of biologics as a first-line therapy, coupled with a surge in regulatory approvals for innovative biologic treatments. The approval of new biologics enhances treatment accessibility and effectiveness, driving overall market expansion. For instance, in December 2024, the U.S. Food and Drug Administration approved two biologic medications for AD, including Nemluvio on December 13, 2024, for moderate-to-severe cases. Additionally, the market is witnessing strong momentum from expanding clinical trials focused on novel and targeted therapies. The ongoing research and development efforts, such as Kymera Therapeutics’ KT-621, an oral protein degrader therapy showing comparable efficacy to Dupixent in early trials, are fostering innovation and offering safer, more convenient treatment alternatives. Such advancements are expected to create significant growth opportunities during the forecast period.

However, the high cost of biologic therapies remains a significant restraint, limiting accessibility among patients in low and middle-income regions. In addition, reimbursement challenges and the need for continuous long-term therapy impose economic burdens on healthcare systems. Despite these challenges, the market outlook remains positive, supported by strong clinical pipelines, ongoing regulatory approvals, and increasing awareness of effective biologic treatment options for atopic dermatitis globally.

Market Highlights

• Drug Class: The PDE4 Inhibitors are expected to register the fastest CAGR of 11.31% owing to improved disease management and a surge in approvals of new drugs.
• Route of Administration: The parenteral segment is growing with the fastest CAGR of 11.06% owing to faster onset of drug action, increased bioavailability of the drug, and long-term treatment efficacy.
• Distribution Channel: The online pharmacies segment registered the fastest CAGR of 10.94%, owing to improved access to advanced therapies, integration of telemedicine, and rising adoption of e-commerce.
• Regional Insights: North America held a dominant share of the global market, accounting for 44.79% in 2025. This growth is attributed to expanding clinical research and increasing disease awareness.

Competitive Players

1. Sanofi 
2. Incyte
3. Otsuka Holdings Co., Ltd
4. Arcutis Biotherapeutics
5. AbbVie Inc.
6. Eli Lilly & Company
7. Astellas Pharma Inc.
8. Pfizer Inc.
9. Leo Pharma
10. Novartis AG
11. Regeneron Pharmaceuticals Inc.
12. Viatris Inc.
13. Galderma Laboratories, L.P.
14. Kymera Therapeutics
15. Glenmark Pharmaceuticals Inc.
16. Bayer AG
17. Maruho Co., Ltd
18. Vanda Pharmaceuticals
19. Botanix SB Inc.
20. Others

Recent Developments

Segmentation

1. By Drug Class (2026-2034)
   1. Corticosteroids
   2. Calcineurin Inhibitors
   3. PDE4 Inhibitors
   4. Biologics
   5. Others
2. By Route of Administration (2026-2034)
   1. Topical
   2. Parenteral
   3. Oral
3. By Distribution Channel (2026-2034)
   1. Hospital Pharmacies
   2. Drug Stores & Retail Pharmacies
   3. Online Pharmacies